Skip to main content
Clinical Trials/NCT02973048
NCT02973048
Completed
Phase 3

Hyperbaric Bupivacaine Versus Hyperbaric Prilocaine 2% for Cesarean Section Under Spinal Anesthesia: a Randomised Clinical Trial

Centre Hospitalier Universitaire Saint Pierre2 sites in 1 country40 target enrollmentMarch 12, 2018

Overview

Phase
Phase 3
Intervention
Hyperbaric bupivacaine
Conditions
Pregnant Women
Sponsor
Centre Hospitalier Universitaire Saint Pierre
Enrollment
40
Locations
2
Primary Endpoint
Time to Regression of Motor Block
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

Over the past 15 years, cesarean delivery is most commonly performed under spinal anesthesia using hyperbaric bupivacaine which provides an adequate sensory and motor block. Despite effective surgical anesthesia, bupivacaine is associated with long duration motor block and dose-dependent maternal hypotension potentially harmful for the fetus. Prilocaine with its new 2% hyperbaric formulation (HP), developed recently, showed rapid onset of action and faster regression of motor block compared to other local anesthetics without noteworthy side-effects when used intrathecally. The aim of this randomized, multicenter, powered clinical trial is to investigate whether HP may be an efficient alternative to hyperbaric bupivacaine for scheduled caesarean delivery under spinal anesthesia, with more rapid rehabilitation and less adverse effects. Our hypothesis is that hyperbaric prilocaine offers shorter motor block and more rapid rehabilitation than bupivacaine.

Registry
clinicaltrials.gov
Start Date
March 12, 2018
End Date
November 8, 2018
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
Centre Hospitalier Universitaire Saint Pierre
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Twin pregnancy
  • History of 2 cesarean section or more
  • Diabetes and gestational diabetes
  • Placenta praevia
  • Congenital foetal abnormality
  • Intrauterine growth retardation
  • Patient in labour
  • Membrane rupture
  • Known allergy to local anaesthetics
  • Standard contraindications to neuraxial block.

Arms & Interventions

Hyperbaric bupivacaine

Hyperbaric bupivacaine 0.5% will be administered at the dose of 10 mg intrathecally associated with 100 µg of morphine and 2.5 µg of sufentanyl.

Intervention: Hyperbaric bupivacaine

Hyperbaric prilocaine

Hyperbaric prilocaine 2% will be administered at the dose of 50 mg intrathecally associated with 100 µg of morphine and 2.5 µg of sufentanyl.

Intervention: Hyperbaric prilocaine

Outcomes

Primary Outcomes

Time to Regression of Motor Block

Time Frame: until complete regression of motor block (up to 4 hours)

Time to regression of motor block is the time between maximal blockade (score 1, as evaluated by the Modified Bromage scale), and no blockade (score 6). Degree of motor blockade is assessed before and 10, 15, 20 minutes after spinal anesthesia, then every 15 minutes until the end of surgery, and thereafter, every 30 minutes until complete regression of motor block

Secondary Outcomes

  • Pain as Assessed by Visual Analogue Scale(up to 24 hours after surgery)
  • Time to Motor Block Onset(From spinal injection of the local anesthetic to bilateral T4 level and during surgery (average 1 hour))
  • Time to First Walk(up to 24h after surgery)
  • Time From Baby Delivery to End of Surgery(average 1 hour)
  • Time to Successful Anesthesia (Successful Sensory Block)(From spinal injection of the local anesthetic to bilateral T4 level (average 20 minutes))
  • Time to Resolution of Sensory Block(until complete release of sensory block (T12-S1) (average 4 hours))
  • Time of Surgery(average 1 hour)
  • Obstetrician Satisfaction(average 1 hour)
  • Midwife Satisfaction(72 hours after surgery)
  • Number of Participants Per Maximal Level of Sensory Block Attained After Spinal Anesthesia(until complete release of sensory block (T12-S1) (average 4 hours))
  • Number of Patients With Hypotension and Use of Vasopressors(up to 2 hours after surgery)
  • Number of Participants With Urinary Retention(up to 4 hours after surgery)
  • Newborn Methemoglobinemia (MetHb)(average 1 hour)
  • Maternal Satisfaction Assessed by Visual Analogic Scale (VASS)(up to 24 hours after surgery)
  • Maternal Rehabilitation Assessed by Visual Analogic Scale (VASR)(up to 72 hours after surgery)
  • Number of Participants With Adverse Events (Nausea, Vomiting, Pruritis, Headache)(up to 72 hours after surgery)
  • Number of Participants With Transient Neurologic Symptoms (TNS)(up to 15 Days after surgery)
  • Time From Spinal Injection to Baby Delivery(average 1 hour)
  • Newborn Apgar Score(up to 10 minutes after baby extraction)
  • Newborn Umbilical pH(average 1 hour)
  • Total Blood Loss(average 1 hour)

Study Sites (2)

Loading locations...

Similar Trials